SUNLIGHT is a randomized phase III study for people diagnosed with refractory metastatic colorectal cancer.
This trial looks at how trifuluridine/tipiracil works in combination with bevacizumab compared to trifluridine/tipiracil when given by itself in patients with refractory mCRC following two chemotherapy regimens.
The use of trifuluridine/tipiracil with bevacizumab or trifuluridine/tipiracil alone as described here is experimental. Because of that, not all risks are known before starting a clinical trial.
The information presented in the following pages about the SUNLIGHT trial is presented by the trial sponsor, Taiho in collaboration with Servier.
The SUNLIGHT trial is currently enrolling people diagnosed with refractory metastatic, confirmed unresectable colorectal cancer with a previously determined RAS status. The cancer must have previously been treated with flouropyrimidines (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody and/or and anti-EGFR monoclonal antibody for RAS wild-type patients.
Doctors call cancer that can’t be completely removed with surgery unresectable.
Metastatic cancer is cancer that has spread to parts of the body away from the colon or rectum, such as the bones or liver.
Phase: Phase III
ClinicalTrials.gov ID number: NCT 04737187
Trial sponsor: Servier